Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GUT-SEQ

Financiado

Cerrado

Single cell analysis of intestinal lymphocytes reveals targets for treatment of...

Single cell analysis of intestinal lymphocytes reveals targets for treatment of inflammatory bowel disease Inflammatory bowel disease (IBD) constitutes an increasing global health burden, yet effective treatments are lacking. Hampering rationale treatment strategies, the human intestinal immune system remains largely unexplored. I have... ver más

31/08/2025

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-01-30

ERC-2019-STG: ERC Starting Grant

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

1.50M€ | Lider

MITSUBISHI LOGISNEXT EUROPE

416.64K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EDIOM Elucidating drivers of human Inflammatory Bowel Disease by n... Cerrado

PRE2019-090334 CARACTERIZACION DE LA BASE CELULAR DE LA ENFERMEDAD INFLAMAT... 98K€ Cerrado

NeurIMM Neuroimmune activation as a novel therapeutic approach for I... 150K€ Cerrado

BecomingCausal Contextual specification of fibroblast-driven causalities in... 2M€ Cerrado

MiRNA-AIEC Role of microRNAs in host responses to Crohn s disease assoc... 194K€ Cerrado

RTI2018-096946-B-I00 CARACTERIZACION DE LA BASE CELULAR DE LA ENFERMEDAD INFLAMAT... 242K€ Cerrado

Duración del proyecto: 67 meses Fecha Inicio: 2020-01-30
Fecha Fin: 2025-08-31

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Inflammatory bowel disease (IBD) constitutes an increasing global health burden, yet effective treatments are lacking. Hampering rationale treatment strategies, the human intestinal immune system remains largely unexplored. I have made seminal contributions to the discovery and characterization of innate lymphoid cells (ILCs) (Nat Immunol 2011, 2013 and 2016, Immunity 2012), revealing that in addition to antigen-specific adaptive T cells, innate equivalents play important roles in mucosal immunity. Determining the complementarity and redundancy of these two lymphocyte systems, acting in concert, is important for our understanding of inflammatory diseases and the development of novel therapies. For this proposal, I am in the beneficial position of having access to unique patient samples as well as established methods for single-cell RNA-sequencing to perform an ambitious and comprehensive molecular dissection of the human intestinal lymphocyte compartments in IBD. With this approach, I will determine parallels between known, and identify novel, subsets of tissue-resident, inflammation-associated, innate and adaptive lymphocytes. Building on this unprecedented molecular characterization, we will take on some of the most pressing clinical problems in IBD by performing longitudinal assessments of intestinal lymphocytes from IBD patients on conventional and biological treatments. As only a fraction of patients respond to treatment, this approach provides a golden opportunity to unveil immunological signatures of treatment response and drug-induced transformation of inflammation in non-responders. Furthermore, we will unfold critical disease mechanisms and reveal novel therapy targets and how they can be used to personalize treatment. In summary, my ambitious, yet feasible, proposal combines state-of-the-art technology with access to unique patient materials. My studies are likely to advance our understanding of the complex intestinal lymphocyte network in IBD.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores